For US residents only.

How Treatment May Help

KISQALI® (ribociclib) + HORMONE THERAPY

Significantly More Effective

The combination of KISQALI® (ribociclib) and letrozole (a type of hormone therapy) was proven to help delay disease progression. KISQALI + letrozole reduced the risk of disease progression by 44% vs letrozole alone. In a clinical trial analysis, more than half of women taking KISQALI + letrozole remained alive and progression free.

KISQALI plus letrozole reduced the risk of disease progression by 44% versus letrozole alone. KISQALI plus letrozole reduced the risk of disease progression by 44% versus letrozole alone.

Shrinks Tumors

KISQALI® (ribociclib) and letrozole worked together to shrink tumors in women who had measurable tumors. 

52.7% of women with measurable tumors taking KISQALI plus letrozole had tumors that shrank or disappeared 52.7% of women with measurable tumors taking KISQALI plus letrozole had tumors that shrank or disappeared
3 out of 4 women saw tumor shrinkage at the first trial check-in (observed 8 weeks after starting treatment). 3 out of 4 women saw tumor shrinkage at the first trial check-in (observed 8 weeks after starting treatment).

This check-in was not designed to measure tumor size reduction. Based on the design of the trial, this result may not have been caused by the treatment.


*49.6% of women taking KISQALI + letrozole saw their tumors shrink in size vs 34.7% of those taking letrozole alone. And 3.1% of women taking KISQALI + letrozole had their tumors completely disappear vs 2.4% of those taking letrozole alone.

The Face of Metastatic Breast Cancer

Watch the KISQALI® (ribociclib) video to meet three women who are representing the experience of living with HR+, HER2- metastatic breast cancer. Listen as they discuss the importance of advocating for yourself, and learn about proven treatment results seen with KISQALI and hormone therapy.

The Face of mBC

Watch the KISQALI TV Commercial to hear three women talk about the experience of receiving a HR +, HER2- metastatic breast cancer diagnosis, and how treatment with KISQALI may help.

The Face of mBC

Watch the KISQALI TV Commercial to hear three women talk about the experience of receiving a HR +, HER2- metastatic breast cancer diagnosis, and how treatment with KISQALI may help.